Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be
beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …

ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …

Background We aimed to determine the impact of tocilizumab use on severe COVID-19
(coronavirus disease 19) pneumonia mortality. Methods We performed a multicentre …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …